Phio Pharmaceuticals Corp. (PHIO): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$7.98M

Year ended 2025-12-31

-$12.20M

Trailing 12 months to 2026-06-30

2012-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$7.98M	n/m	2026-03-05, From 2025-01-01
2024-12-31	-$7.11M	n/m	2026-03-05, From 2024-01-01
2023-12-31	-$10.75M	n/m	2025-03-31, From 2023-01-01
2022-12-31	-$12.13M	n/m	2024-04-01, From 2022-01-01
2021-12-31	-$11.86M	n/m	2023-03-22, From 2021-01-01
2020-12-31	-$8.80M	n/m	2022-03-22, From 2020-01-01
2019-12-31	-$8.64M	n/m	2021-03-25, From 2019-01-01
2018-12-31	-$7.52M	n/m	2020-03-26, From 2018-01-01
2017-12-31	-$9.51M	n/m	2019-03-27, From 2017-01-01
2016-12-31	-$7.76M	n/m	2018-03-26, From 2016-01-01
2015-12-31	-$7.32M	n/m	2017-03-30, From 2015-01-01
2014-12-31	-$7.76M	n/m	2016-03-30, From 2014-01-01
2013-12-31	-$6.31M	n/m	2014-03-28, From 2013-01-01
2012-12-31	-$5.06M	n/a	2014-03-28, From 2012-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Phio Pharmaceuticals Corp. (PHIO)	2025-12-31	-$7.98M	n/m
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	-$11.0K	n/m
BriaCell Therapeutics Corp. (BCTX)	2025-07-31	-$28.17M	n/m
Annovis Bio, Inc. (ANVS)	2025-12-31	-$25.62M	n/m
Abvc Biopharma, Inc. (ABVC)	2025-12-31	-$2.99M	n/m
Moleculin Biotech, Inc. (MBRX)	2025-12-31	-$22.73M	n/m
Jyong Biotech Ltd. (MENS)	2025-12-31	-$3.04M	n/m
Nexentis Technologies Inc. (NXTS)	2025-12-31	-$3.81M	n/m
Quoin Pharmaceuticals Ltd. (QNRX)	2025-12-31	-$13.54M	n/m

Compare PHIO, EMMA, BCTX, ANVS side by side · Screen every company in Pharmaceutical Preparations ↗